Retrospection of the USFDA‐Approved Halogenated Drugs and Their Implication in Medicinal Chemistry and Drug Discovery: A Perspective of Approved Drugs Between 2019 and 2024
Archiv der Pharmazie · 2026
DOI: 10.1002/ardp.70190 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, 2026. Verfasst von Nemat Ali und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Drug Discovery, Halogens, Drug Approval. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 120 Literaturangaben. Gefördert von: Deanship of Scientific Research, Deanship of Scientific Research, King Saud University.
Abstract (Originalsprache)
Halogens are utilized in drug discovery and development due to their ability to precisely tune the molecular properties of drug candidates. The halogen substituents play a crucial role in determining the stability, lipophilicity, and receptor binding, as well as significantly influencing the metabolic fate of the drug candidates. Literature insights reveal that 30% of all small molecules approved by the USFDA carry a halogen as a substituent. Considering the vital importance of halogen‐containing substituents, we have compiled concise information on halogen‐containing US FDA‐approved drugs over the last decade (2019–2024). The articles provide information on pharmacological conditions, targets, available formulations, and pharmacokinetic details for each approved drug that possesses a halogen as a substituent, along with its corresponding chemical structure. The analysis revealed that 37 new drugs were approved to combat cancer (13), followed by rare diseases (6), viral infections (3), and other conditions during the analysis period. Furthermore, the chemistry of halogens, along with their medicinal applications, provides key evidence on how halogens have been explored to enhance the pharmacokinetics and pharmacodynamics of drug candidates. The analysis of approved dosage forms revealed that 23 were solid dosage forms, comprising 24 tablet forms, 8 capsules, and 1 powder. CYP3A4 is a major contributor in the metabolism of 6 drugs, followed by CYP3A (3), CYP1A2 (2), CYP3A4/5 (2), and one each by CYP2C9, UGT1A9, CYP2C8, aldehyde oxidase, and other non‐CYP enzymes. The present medicinal chemistry perspective is thus expected to be a valuable read for the medicinal and allied sciences community.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
- Department of Anatomy and Physiology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
- Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.
- Centre of Research Impact and Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.
- Department of Pharmacology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
- Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, Uttarakhand, India.
ORCID-Profile: Nemat Ali, Nisha Bansal
Förderung
- Deanship of Scientific Research
- Deanship of Scientific Research, King Saud University
Zitieren
APA
Ali, N., Alotaibi, F. T., Babu, M. A., Singh, T. G., Alaseem, A. M., Tyagi, Y., & Bansal, N. (2026). Retrospection of the USFDA‐Approved Halogenated Drugs and Their Implication in Medicinal Chemistry and Drug Discovery: A Perspective of Approved Drugs Between 2019 and 2024. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70190
Vancouver
Ali N, Alotaibi FT, Babu MA, Singh TG, Alaseem AM, Tyagi Y, et al. Retrospection of the USFDA‐Approved Halogenated Drugs and Their Implication in Medicinal Chemistry and Drug Discovery: A Perspective of Approved Drugs Between 2019 and 2024. Archiv der Pharmazie. 2026. doi:10.1002/ardp.70190
BibTeX
@article{Ali2026,
author = {Ali, Nemat and Alotaibi, Fahad T and Babu, M Arockia and Singh, Thakur Gurjeet and Alaseem, Ali M and Tyagi, Yogita and Bansal, Nisha},
title = {Retrospection of the USFDA‐Approved Halogenated Drugs and Their Implication in Medicinal Chemistry and Drug Discovery: A Perspective of Approved Drugs Between 2019 and 2024},
journal = {Archiv der Pharmazie},
year = {2026},
doi = {10.1002/ardp.70190}
}
EUVIMED